FAIL-T (AFP, AST, tumor sIze, ALT, and Tumor number): a model to predict intermediate-stage HCC patients who are not good candidates for TACE

BACKGROUND: Patients with un-resectable hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE) are a diverse group with varying overall survival (OS). Despite the availability of several scoring systems for predicting OS, one of the unsolved problems is identifying patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaewdech, Apichat, Sripongpun, Pimsiri, Assawasuwannakit, Suraphon, Wetwittayakhlang, Panu, Jandee, Sawangpong, Chamroonkul, Naichaya, Piratvisuth, Teerha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10185803/
https://www.ncbi.nlm.nih.gov/pubmed/37200967
http://dx.doi.org/10.3389/fmed.2023.1077842

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10185803/
https://www.ncbi.nlm.nih.gov/pubmed/37200967
http://dx.doi.org/10.3389/fmed.2023.1077842

Ejemplares similares